Shiro Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-12-2024
- Paid Up Capital ₹ 4.50 M
as on 16-12-2024
- Company Age 12 Year, 28 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.39 M
as on 16-12-2024
- Revenue %
(FY 2022)
- Profit -2408.54%
(FY 2022)
- Ebitda -104.22%
(FY 2022)
- Net Worth -66.17%
(FY 2022)
- Total Assets -7.41%
(FY 2022)
About Shiro Pharmachem
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.50 M.
The company currently has active open charges totaling ₹4.39 M.
Nupura Parchure and Balvant Parchure serve as directors at the Company.
- CIN/LLPIN
U24233MH2012PTC238300
- Company No.
238300
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Nov 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Shiro Pharmachem Private Limited offer?
Shiro Pharmachem Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, API Intermediate, Biomass Briquettes, Catalysts, Methyl Ethyl Ketone Peroxide.
Who are the key members and board of directors at Shiro Pharmachem?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nupura Parchure  | Director | 27-Nov-2012 | Current |
| Balvant Parchure | Director | 22-Apr-2014 | Current |
Financial Performance of Shiro Pharmachem.
Shiro Pharmachem Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 2408.54% decrease in profit. The company's net worth observed a substantial decline by a decrease of 66.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shiro Pharmachem?
In 2020, Shiro Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 31 Mar 2022 | ₹0.20 M | Open |
Bank Of India Creation Date: 07 Jan 2022 | ₹0.69 M | Open |
Bank Of India Creation Date: 19 Jan 2018 | ₹0.30 M | Open |
How Many Employees Work at Shiro Pharmachem?
Unlock and access historical data on people associated with Shiro Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shiro Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shiro Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
